Onco’Zine
Onco’Zine is designed to provide valuable information and assistance to doctors and healthcare providers who care for cancer patients.
Outlet metrics
Global
#4240210
United States
#1464901
Health/Health Conditions and Concerns
#3892
Articles
-
2 weeks ago |
oncozine.com | Danielle Garcia
Positive high-level results from a planned interim analysis of the SERENA-6 Phase 3 study (NCT04964934) confirm that camizestrant, an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist for the treatment of HR-positive breast cancer, in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrate a highly statistically significant and clinically meaningful improvement in the...
-
3 weeks ago |
oncozine.com | Danielle Garcia
Results from the international phase 3 AMPLITUDE clinical trial (NCT04497844) sponsored by Janssen Research & Development, found that adding niraparib (Zejula®, Tesaro) to abiraterone acetate (Zytiga™; Johnson & Johnson)* + prednisone (AAP) can help slow cancer growth for people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations.
-
3 weeks ago |
oncozine.com | Danielle Garcia
The combination of sacituzumab govitecan (Trodelvy®; Gilead Sciences; See ADC Drugmap)* + pembrolizumab (Keytruda®; Merck & Co/MSD) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care (SoC) pembrolizumab plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).[1] Sacituzumab govitecan given in combination with pembrolizumab resulted in a median progression-free survival (PFS) of 11.2...
-
4 weeks ago |
oncozine.com | Danielle Garcia
New clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune checkpoint will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 – June 3, 2025, in Chicago, IL, USA.
-
1 month ago |
oncozine.com | Danielle Garcia
At the upcoming annual meeting of annual meeting of the American Society of Clinical Oncology, held May 30 through June 3, 2025 in Chicago, Illinois., EMD Serono* will highlight new data from studies across more than 12 tumor types. Some of the studies and investigational agents involve the most challenging cancers.
Onco’Zine journalists
Contact details
Address
123 Example Street
City, Country 12345
Contact Forms
Contact Form
Website
http://oncozine.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →